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Purpose: Pain ﬂare is a temporary increase in pain and is a potential side effect of radiotherapy
treatment. However, its incidence has been reported only in recent studies, and with great variability.
A few studies have reported on the use of dexamethasone as a prophylactic agent in the prevention of
pain ﬂare. The objective of this study is to present a review of the available literature regarding the
incidence of pain ﬂare and use of dexamethasone as a preventative measure.
Methods: A literature search was conducted in PubMed using subject keywords including: “radiation
therapy”, “stereotactic radiation therapy”, “bone metastases”, “pain ﬂare”, and “dexamethasone”.
The search was limited to English only but not restricted to any time period. Additionally, a search
was also conducted in the American Society for Therapeutic Radiology and Oncology (ASTRO) 2014 book
of published abstracts. Inclusion criteria were primary studies published with full text and/or abstracts
only. Letters to the editor were excluded.
Results: A total of 11 studies were selected, two of which were abstracts published by ASTRO in 2014.
Seven articles investigated pain ﬂare and/or dexamethasone use for conventional external beam
radiation therapy (EBRT) while the remaining four investigated stereotactic body radiation therapy
(SBRT). Pain ﬂare incidence ranged from 2 to 44% for EBRT and 10 to 68% in SBRT. The use of
dexamethasone also showed to be effective in both the prophylaxis and treatment of pain ﬂare.
Conclusions: Pain ﬂare has been established as an acute toxicity of both EBRT and SBRT, although its
incidence is widely variable due to differences in data collection. The use of dexamethasone in the
prophylaxis of pain ﬂare is efﬁcacious. Future studies are required in order to both optimize the reporting
of pain and the dexamethasone regimens in the prevention of pain ﬂare.
& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bone metastases are exceedingly common among advanced
cancer patients, especially in those with breast, prostate, and lung
carcinomas [1,2]. They are a cause of great morbidity and result in
signiﬁcant pain in 50–75% of patients at some point throughout
the course of their illness [2–4]. Bone metastases can also lead to
hypercalcemia, skeletal complications including pathological frac-
tures and spinal cord compression, and have a negative impact on
quality of life (QOL) [1,5,6].
External beam radiation therapy (EBRT) is recommended for
the relief of symptomatic bone metastases [1,5,6]. Studies have
proven it to be both cost-effective and efﬁcacious, with up to 80%
of treated patients experiencing at least some pain relief [3,6].
Moreover, it has few associated toxicities, many of which are
temporary and minor in nature [6].
Recent technological developments have led to an increased
use of stereotactic body radiation therapy (SBRT) for the treatment
of select tumors, most commonly to the liver, lung, or bone [7,8].
This technique is employed with a locally curative intent and
delivers more radical doses of radiation with great accuracy [9].
For spinal metastases, SBRT allows for locally ablative doses of
radiation to the target and limits the spinal cord or cauda to
thresholds below the dose of myelopathy [6]. SBRT to the spine
delays tumor progression and provides long-term pain control and
maintenance or even improvement in QOL [7]. Long term compli-
cations of spine SBRT, unique from conventional EBRT, include
vertebral compression fractures and, much less likely, radiation
myelopathy. Acute adverse events are similar to conventional
radiotherapy and are usually self-limiting [8].
Pain ﬂare, deﬁned as a “temporary worsening of bone pain in the
treated metastatic site” [2], has been previously documented as a side
effect of radiopharmaceutical and hormonal therapy [2,10,11].
Although it is a recognized side-effect of radiation treatment as well,
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only recent studies have attempted to accurately document its
incidence in patients treated with EBRT or SBRT [2,4,7–13]. These
studies report incidences reaching as high as 68% for SBRT and 44% for
EBRT [8]. A qualitative study published by Hird et al. [14] discusses
patient perspectives and the impact of pain ﬂare on QOL. Overall,
patients describe interference with daily activities and general func-
tioning, as well as anxiety and worry regarding the success of the
treatment. Typical pain ﬂare management entails an increase in
analgesic use, leaving the patient at risk of associated adverse events
including dry mouth, drowsiness, and constipation [14]. Moreover, the
majority of patients felt that their pain was not adequately relieved by
increased analgesics. Rather, 85% of patients stated that the optimal
management of pain ﬂare requires prophylaxis [14].
Dexamethasone is an anti-inﬂammatory steroid medication
that has been shown to be effective as a prophylactic agent against
pain ﬂare [4,8,12]. It is hypothesized that the dexamethasone
reduces edema within the periosteum of the treated bone [15].
With a half life of 36–54 h, it may be administered to patients
throughout the duration of treatment and for a few days post
treatment in order to curb the debilitating effects of pain ﬂare [12].
The objective of this report is to present the currently available
literature documenting the incidence of pain ﬂare in both conven-
tional and stereotactic radiation therapy techniques. Furthermore, it
will summarize the use of dexamethasone in early clinical trials as a
prophylactic measure against the occurrence of pain ﬂare.
2. Methods
A literature search was conducted in PubMed. It was limited to
English articles only, but was not restricted to any time period. The
American Society for Therapeutic Radiology and Oncology (ASTRO)
2014 book of published abstracts was also screened for potential
relevant studies. Keywords and subject headings for searches
included “radiation therapy”, “stereotactic radiation therapy”, “bone
metastases”, “pain ﬂare”, and “dexamethasone”. Inclusion criteria
were primary studies published with full text and/or abstracts only.
Letters to the editor and commentaries were excluded.
Abstracts and articles generated by the search were screened
based on title ﬁrst, then abstract or full text, independently by RM
and LR. If there was a disagreement for inclusion or exclusion of an
article, a discussion ensued until a consensus was reached.
3. Results
A total of eleven studies published between 2005 and 2014 were
identiﬁed as relevant. This includes nine full text articles and two
abstract publications extracted from the ASTRO 2014. Seven studies
investigated EBRT with two additionally investigating prophylactic
treatment of pain ﬂare with dexamethasone and one investigating
prophylaxis with a methylprednisolone infusion. Four studies
investigated pain ﬂare resulting from stereotactic radiation therapy,
only one of which included dexamethasone as a prophylactic agent.
A summary of the studies and their characteristics is presented in
Table 1. The incidence of pain ﬂare, duration of pain ﬂare, and
possible use of dexamethasone, if applicable, is reported in Table 2.
3.1. External beam radiation therapy
A total of seven studies have documented the incidence of pain
ﬂare in patients treated with EBRT to symptomatic bone metastases,
three of which included an investigation of pain ﬂare prophylaxis with
a steroid medication [2,4,10–13,16]. All studies collected data such as
pain score and analgesic intake prospectively using questionnaires at
baseline, daily during, and daily after treatment completion for a set
duration of time. Speciﬁc data collection methods can be found in
Table 1.
The ﬁrst study to investigate the incidence of pain ﬂare was
published in 2005 [10]. Pain ﬂare was deﬁned in their study as
either a 2-point increase in worst pain on a scale of 0–10 with no
decrease in analgesic intake, or as a 25% increase in analgesic
intake with no decrease in worst pain score. Between June 2000
and February 2001, 88 patients were accrued to the study. The
incidence of pain ﬂare was 14% on day one for patients who
received 8 Gy in 1 fraction, and 15% on day one for patients who
received 20 Gy in 5 fractions [10].
Following up with this study in 2007, the authors [12] pub-
lished a study investigating the use of dexamethasone for the
prophylaxis of pain ﬂare. All 33 patients accrued to the study were
prescribed two tablets of 4 mg dexamethasone by mouth one hour
before treatment. Using the Brief Pain Inventory (BPI) to collect
analgesic information and worst pain score, pain ﬂare incidence in
this population was reported to be 24% [12].
In contrast to the previous two studies, Loblaw et al. [11]
collected pain scores using the Present Pain Intensity (PPI) ques-
tionnaire and developed two working deﬁnitions of pain ﬂare:
(1) a 2-point increase in the PPI with no decrease in analgesic
score, or a 50% increase in analgesic score with no decrease in PPI
on at least two consecutive days; and (2) a 2-point increase in PPI
with no decrease in analgesic score or a 25% increase in analgesic
score with no decrease in PPI on at least two consecutive days. The
authors collected pain scores prospectively using the PPI at base-
line, in a daily diary for the ﬁrst week following treatment, and
then at 14, 30, and 60 days post treatment. The incidence of pain
ﬂare was 34.1% and 40.9% using each deﬁnition, respectively [11].
Hird et al. [2] published a comprehensive study in 2009 with
results on pain ﬂare incidence from three Canadian Centres. A total
of 111 patients were included in the study, of which 41% docu-
mented pain ﬂare. Eighty percent of those who experienced pain
ﬂare also reported it to be within the ﬁrst ﬁve days following
treatment. A phase II trial was then published in 2009 by Hird
et al. [4], in which 8 mg of dexamethasone was prescribed to all
patients and taken at least one hour before daily radiotherapy and
for three consecutive days following completion. Twenty-two
percent of the 41 accrued patients reported pain ﬂare with a
median duration of one day.
A recent study published in abstract form only reported the
incidence of pain ﬂare in patients treated with EBRT to bone
metastases [16]. This study collected worst pain scores and
analgesic consumption prospectively before, daily during, and for
ten days post-treatment. Of a total patient population of 94, 42
(44.7%) were documented to have pain ﬂare. The median duration
of pain ﬂare was two days and the majority (88%) occurred
between days one to ﬁve post-treatment [16].
In a double-blind randomized study, one hundred twenty patients
with vertebral metastases during the two week short-course EBRT
were randomized to methylprednisolone versus placebo resulting in
pain ﬂare incidence of 6.6% versus 20% respectively [13].
3.2. Stereotactic body radiation therapy
Four studies investigated the incidence of pain ﬂare in patients
treated with SBRT [7–9,17]. Three of the four studies deﬁned pain ﬂare
as (1) at least a 2-point increase in worst pain score, (2) at least a 25%
increase in opioid intake, or (3) the initiation of steroids [7,8,17].
The fourth study measured pain ﬂare according to the Common
Terminology Criteria for Adverse Events (CTCAE) version 4.03 [7].
Chiang et al. [8] published the ﬁrst study in March 2013 and
focused speciﬁcally on SBRT for patients with spinal metastases. Data
was collected prospectively using the BPI at baseline, during treat-
ment, and ten days post follow-up. The authors found that 28 of 41
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(68.3%) accrued patients experienced pain ﬂare and the most common
occurrence was before day 3 following completion of treatment (71%)
[8]. In contrast, Owen et al. [9] investigated SBRT for non-spine bone
metastases. Data collection in this study was completed retrospec-
tively; incidence of pain ﬂare was determined from clinical notes
based on follow-up visits typically one to threemonths after treatment
completion. A total of 74 patients were evaluable, and the reported
incidence of pain ﬂare was much lower at 10% [9].
A similar study design was used by Pan et al. [7] who completed a
secondary analysis of phase I and II trials on spine SBRT. Pain scores
were collected in a retrospective manner through completion of the
BPI at baseline and one and two weeks after completion of single
Table 1
Characteristics of the literature investigating pain ﬂare incidence and use of dexamethasone.
Author
(year)
Technique
(EBRT/
SBRT)
Study design and data collection
(retrospective/prospective)
Population Pain ﬂare deﬁnition Ref.
Chow
(2005)
EBRT Prospective, medications and pain score on a 0–10
score were collected at baseline, daily during
treatment, and daily for 10 days post treatment
June 2000–Feb 2001 n¼88 A 2-point increase in pain scale of 0–10 (0
meaning no pain, 10 meaning worst possible pain)
with no decrease in analgesic intake or 25%
increase in analgesic intake with no decrease in
pain score. Pain score and analgesic intake must
return back to normal to differentiate pain ﬂare
from pain progression
[10]
Chow
(2007)
EBRT Prospective, medications and pain score were
recorded using the BPI at baseline, and daily for 10
days following treatment
n¼33 Patients treated with 8 Gy/1
to bone metastases
A 2-point increase in pain scale of 0–10 (0
meaning no pain, 10 meaning worst possible pain)
with no decrease in analgesic intake or 25%
increase in analgesic intake with no decrease in
pain score. Pain score and analgesic intake must
return back to normal to differentiate pain ﬂare
from pain progression
[12]
Loblaw
(2007)
EBRT Prospective, medications were recorded and pain
collected using the Present Pain Intensity (PPI) at
baseline, in a daily diary for the ﬁrst week
following treatment, at 14 days, 1 month, and
3 months post treatment
Jan 29, 1997–Jan 20, 1999 n¼44
Patients randomized to receive
8 Gy/1 or 20 Gy/5 for
symptomatic bone metastases
Firstly as a 2-point increase in the PPI with no
decrease in analgesic score or a 50% increase in
analgesic score with no decrease in PPI on at least
two consecutive days. Also deﬁned as a 2-point
increase in PPI with no decrease in analgesic score
or a 25% increase in analgesic score with no
decrease in PPI on at least two consecutive days
[11]
Hird
(2009)
EBRT Prospective; pain and medications were recorded
with the BPI at baseline and then using a daily
diary during treatment and 10 days after
completion of treatment
Feb 2006–May 2008 n¼111 A 2-point increase in pain scale of 0–10 (0
meaning no pain, 10 meaning worst possible pain)
with no decrease in analgesic intake or 25%
increase in analgesic intake with no decrease in
pain score. Pain score and analgesic intake must
return back to normal to differentiate pain ﬂare
from pain progression
[2]
Hird
(2009)
EBRT Prospective; pain, medications, and quality of life
recorded through the BPI and EORTC QLQ-C30 at
baseline, daily for 10 days, and at 6 weeks
following treatment
Jan 2007–July 2008 n¼41 Patients
treated with a single 8 Gy to bone
metastases
A 2-point increase in pain scale of 0–10 (0
meaning no pain, 10 meaning worst possible pain)
with no decrease in analgesic intake or 25%
increase in analgesic intake with no decrease in
pain score. Pain score and analgesic intake must
return back to normal to differentiate pain ﬂare
from pain progression
[4]
Gomez-
Itur-
riaga
(2014)
EBRT Prospective; worst pain scores and analgesic
consumption were collected before, daily during,
and 10 days post treatment
June 2010–Dec 2013 n¼94 A 2-point increase in pain scale of 0–10 (0
meaning no pain, 10 meaning worst possible pain)
with no decrease in analgesic intake or 25%
increase in analgesic intake with no decrease in
pain score
[16]
Yousef
(2014)
EBRT Prospective; BPI collected at baseline. Worst pain
scores and analgesic information collected before,
daily during, and at the end of follow-up
Nov 2012–May 2013 n¼120, with
vertebral metastases
A 2-point increase in worst pain score with no
decrease in analgesic intake or a 25% increase in
daily analgesic intake with no decrease in worst
pain score
[13]
Chiang
(2013)
SBRT Prospective, data collected using BPI at baseline,
during, and for 10 days following treatment
Feb 2010–April 2012 n¼41 (1) A 2-point increase in worst pain score with no
decrease in analgesic intake, (2) 25% increase in
analgesic intake as compared with baseline, and
no decrease in worst pain score, or (3) if
corticosteroids were initiated during or after SBRT
due to pain
[8]
Owen
(2013)
SBRT Retrospective, pain ﬂare documented during
follow-up clinic visits typically 1–3 months after
treatment
Jan 1, 2008–Aug 1, 2012 n¼74 Measured using the CTCAE v.4.03 [9]
Pan
(2014)
SBRT Retrospective, pain at metastatic sites measured
using BPI (including current pain medications and
concurrent medications). Follow-up with BPI
occurred 1 and 2 weeks after treatment for single
fraction courses, and 2 and 4 weeks after
treatment for multiple fraction courses
2002–2011 n¼195 First identiﬁed through clinical notes indicating
an increase in pain at the site of treatment. By
survey, deﬁned as either (1) an Z2-point increase
in worst pain score, (2) an Z25% increase in
opioid intake, or (3) initiation of steroids
[7]
Khan
(2014)
SBRT Prospective; patients competed the BPI daily
during treatment and for 10 days post treatment
Feb 2012–Feb 2014 n¼47 a 2-point increase in worst pain score with no
decrease in analgesic intake or 25% increase in
analgesic intake as compared with baseline, and
no decrease in worst pain score
[17]
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fraction SBRT, or two and four weeks after completion of multiple
fraction SBRT. Of 195 patients treated, approximately 23% experienced
pain ﬂare. The overall median time to pain ﬂare was ﬁve days
according to survey, however this decreased to 2.5 days when based
solely on clinical evaluation [7].
The only study to investigate the use of prophylactic dexametha-
sone for pain ﬂare for SBRT patients was published in an abstract by
Khan et al. [17]. Dexamethasone was taken a day prior to treatment,
daily during treatment, and for four days post treatment. Group one
consisted of 24 patients prescribed 4 mg dexamethasone, of which
25% experienced pain ﬂare. Group two consisted of 23 patients who
were prescribed 8 mg of dexamethasone and the incidence of pain
ﬂare was considerably less, at only 13%. Pain ﬂare occurred most often
during treatment and up to day one following completion (66% of
patients). Data was collected prospectively through the completion of
the BPI daily during treatment and for 10 days following completion
[17].
4. Discussion
Bone pain as a result of bone metastases is a well documented
occurrence in advanced cancer patients [2–4]. Palliative external
beam radiation therapy, and more recently stereotactic body
radiation therapy, are effective and well-tolerated treatments for
the relief of cancer related bone pain [1,5,6]. Pain ﬂare, a
temporary exacerbation of pain closely following completion of
treatment, is a recognized acute toxicity of both treatment
techniques [2]. We completed a comprehensive review of the
currently available literature documenting the incidence of pain
ﬂare and the prophylactic use of dexamethasone to decrease the
incidence.
The method of data collection is an inherently critical factor in
study design and can greatly inﬂuence study results and their
interpretation. It is particularly relevant to this current review when
examining the widespread discrepancies in pain ﬂare incidence,
particularly among SBRT studies. Both Pan et al. [7] and Owen et al.
[9] collected data retrospectively and reported incidence rates of
23% and 10%, respectively. These incidences are considerably less
than the 68% reported by Chiang et al. [8] in 2013, in a study that
employed prospective collection methods. Retrospective studies
in general may be subject to recall bias, where patients do not
accurately recall the events that they have experienced. Especially
when the goal of treatment is to provide pain relief, these patients
may be more focused on the improvement of their symptoms rather
than the transient exacerbation of them. Noteworthy are that
conventional EBRT studies obtained data prospectively and the
collective incidence of pain ﬂare was consistently around 40%.
Table 2
Characteristics of pain ﬂare and use of dexamethasone.
Author (Year) Incidence of pain ﬂare (%) Time to pain ﬂare duration of pain ﬂare Intervention with dexamethasone Ref.
Chow (2005) 14% on day 1 and 2 for patients who received a
single treatment 15% on day 1 for patients who
received 20 Gy/5 Overall range of pain ﬂare
from 2 to 16%
Most commonly experienced days 1 and
2 post-treatment (14% and 16%, respectively)
N/A [10]
Chow (2007) 24% experienced pain ﬂare during 10-day
follow-up
Of the 24% who experienced pain ﬂare, two of
these patients experienced a one-day pain ﬂare
on day 3, three patients had 1-day pain ﬂare on
day 7, three had prolonged pain ﬂare (one from
day 2–4, one days 4–6, and one days 3–8)
All patients were prescribed two
tablets of 4 mg dexamethasone by
mouth 1 h before radiation treatment
[12]
Loblaw (2007) Using the ﬁrst pain ﬂare deﬁnition: 34.1%
Using second pain ﬂare deﬁnition: 40.9%
Median duration of three days N/A [11]
Hird (2009) Overall incidence of 40%. For patients treated
with 8 Gy/1, incidence was 39%, and for those
treated with multiple fractions, the incidence
was 41%.
Pain ﬂare occurred within ﬁrst 5 days following
radiation in 80% of patients
N/A [2]
Hird (2009) 22% experienced a total of 11 pain ﬂares Median duration of pain ﬂare was 1 day, and
these occurred on days 1, 2, and 4. Two
separate 3 day pain ﬂares occurred on days
6 and 8. Six of 11 (55%) pain ﬂares occurred on
day 5.
Dexamethasone was prescribed 8 mg
orally at least 1 h before radiotherapy
and 8 mg daily for 3 consecutive days
after treatment
[4]
Gomez-Iturriaga
(2014)
44.7% Median duration of 2 days Majority of pain
ﬂares occurred days 1–5 (88%)
N/A [16]
Yousef (2014) 6.6% in those who received a
methylprednisolone infusion 20% in those who
received placebo
Methylprednisolone Group: two patients with
1 day pain ﬂare up on day 3, one patient with
1 day pain ﬂare on day 7, one patient with
2 day pain ﬂare on days 2–3 Placebo Group:
ﬁve patients had 3 day pain ﬂare days 4–6,
other three had 6 day pain ﬂare on days 4–9
A methylprednisolone infusion was
administered to 60 patients for two
hours before treatment. For the other
60 patients, placebo (saline solution)
was infused.
[13]
Chiang (2013) 68.3% Most commonly before day 3 following SBRT
(71%)
n¼13 started on rescue
dexamethasone either during or within
10 days of completing treatment as a
result of pain, after which pain scores
decreased signiﬁcantly over time
[8]
Owen (2013) 10% N/A N/A [9]
Pan (2014) 23% Overall median time to pain ﬂare of 5 days;
when determined by clinical evaluation median
time to pain ﬂare was 2.5 days
Of 27 patients who were identiﬁed
with pain ﬂare by clinical evaluation, 16
(59%) were prescribed dexamethasone
[7]
Khan (2014) 19% overall 25% in patients who received 4 mg
(24) and 13% in patients who received 8 mg
(23)
Occurred most frequently during and up to day
1 post treatment (66%)
Dexamethasone was prescribed to all
patients, with 24 patients prescribed
4 mg and 23 patients prescribed 8 mg.
All patients took dexamethasone 1 hr
prior to daily treatment and for 4 days
post treatment
[17]
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Dexamethasone, with its anti-inﬂammatory properties, has
been shown to be an effective medication in the treatment of
pain ﬂare and is hypothesized to prevent the phenomenon as well
[12]. Despite a lack of literature investigating this hypothesis,
currently published phase I and II trials have provided compelling
preliminary evidence for its use as a prophylactic agent in both
EBRT and SBRT treatment settings. Khan et al. [17] conducted the
ﬁrst and only study where patients receiving SBRT to the spine
were prescribed either 4 mg or 8 mg dexamethasone once daily
during treatment and four days post-treatment. Pain ﬂare inci-
dence was reported at 25% and 13% for each dose, respectively.
This is signiﬁcantly less than the previously reported 68% of
patients at the same institution with similar patients who experi-
enced pain ﬂare without any prophylaxis [8]. Similar to the study
conducted by Khan et al. [17], dexamethasone prophylaxis of
varying regimens was used by Chow et al. [12] and Hird et al.
[4] in patients treated with EBRT. Incidence of pain ﬂare in these
studies decreased from an average of 40% to 22–24% [12].
Despite the apparent beneﬁt of prophylactic dexamethasone in
decreasing the incidence of pain ﬂare, there is a lack of consensus
on dosage, frequency, and duration of intake. The majority of pain
ﬂare incidence occurs within days one to ﬁve following comple-
tion of radiation treatment [2,4,16]. With a half life of 36–54 h,
theoretically dexamethasone prescribed for four days post-
treatment should effectively prevent pain ﬂare up to and including
day ﬁve [4,12]. Results published by Khan et al. [17] conﬁrm this
hypothesis, as patients prescribed 8 mg of dexamethasone during
and four days post treatment had pain ﬂare incidence of only 13%.
The incidence of pain ﬂare in EBRT studies after prophylactic
dexamethasone use remains higher at approximately 22–24%,
however, these studies prescribed dexamethasone only on the
day of treatment, or on the day of treatment with three additional
subsequent days [4,12]. The greater incidence of pain ﬂare in these
studies as compared to the study by Khan et al. [17] may be related
to the shorter duration of dexamethasone.
In determining the best possible dose of dexamethasone, it is
equally important to consider optimal prophylaxis as well as adverse
events and contraindications related to the medication itself. For
instance, dexamethasone has a role in immune-suppression, which
may lead to increased susceptibility for infection [18]. In already
vulnerable populations such as those with advanced cancer, this risk
must be weighed appropriately. Dexamethasone may also increase
blood sugar levels putting those with diabetes at risk, or activate and
further complicate ulcers and other digestive problems [18]. Other
common side effects of dexamethasone include an increased appetite,
trouble sleeping, and excess ﬂuid retention or swelling in the face,
hands or feet [18]. Especially in palliative cancer patients, where the
goal of treatment often focuses on maintenance or improvement of
QOL, the dosage and duration of dexamethasone must be optimally
suited to maximize the prevention of pain ﬂare while minimizing
further side effects from the medication itself.
Although the use of dexamethasone appears to be protective
against pain ﬂare, some patients still endure the painful side effect.
This occurs in approximately 13% of patients receiving spine SBRT,
as reported by Khan et al. [17], and 22% of patients receiving EBRT,
as reported by Hird et al. [4]. Why is it that these patients do not
beneﬁt from the anti-inﬂammatory properties of dexamethasone
as the majority of patients seem to? The answer to this question
may be found in the analysis of biomarkers or DNA of the patient.
Determining what these markers are and developing methods of
prophylaxis for these patients should be objectives of future
studies in order to provide the best possible care to all patients.
Two studies are ongoing that promise to be paramount in the
prescription of dexamethasone in the prophylaxis of pain ﬂare.
NCIC CTG is currently investigating the use of 8 mg dexametha-
sone daily on the day of treatment and four days post-treatment
versus placebo of the same duration (NCT01248585) [19]. The
primary outcome of this study is the incidence of pain ﬂare, with
secondary outcomes including changes in pain scores, analgesic
use, and QOL. The results of this study may be able to help identify
those patients who will not beneﬁt from prophylactic dexametha-
sone. Similarly, Westhoff et al. [15] are collaborating with twelve
radiotherapy departments in the Netherlands to investigate pla-
cebo for four days versus 8 mg dexamethasone for one day with
placebo for three days, versus 8 mg dexamethasone for four days
(NCT01669499). Again, the primary outcome is the incidence of
pain ﬂare, with secondary outcomes including pain scores, QOL,
and side effects. Similar studies should be undertaken in a
stereotactic body radiation therapy setting, in order to conﬁrm
the ﬁndings by Khan et al. [17].
5. Conclusion
Bone metastases are very prevalent in advanced cancer
patients and often lead to signiﬁcantly debilitating pain. Radiation
therapy is an effective treatment of painful bone metastases and is
often well tolerated with little toxicity. However, acute pain ﬂare
has been previously recognized and is reported to have an
incidence as high as 68% in SBRT and 40% in patients treated
EBRT. Dexamethasone appears to decrease the incidence of pain
ﬂare. Ongoing clinical trials will conﬁrm the utility of dexametha-
sone and shed some light on the optimal duration, dose and
frequency required to prevent pain ﬂare.
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